WO2021234554A2 - Nouvelle composition pour le traitement d'infections virales - Google Patents

Nouvelle composition pour le traitement d'infections virales Download PDF

Info

Publication number
WO2021234554A2
WO2021234554A2 PCT/IB2021/054246 IB2021054246W WO2021234554A2 WO 2021234554 A2 WO2021234554 A2 WO 2021234554A2 IB 2021054246 W IB2021054246 W IB 2021054246W WO 2021234554 A2 WO2021234554 A2 WO 2021234554A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
carbocisteine
agent
combination
solution
Prior art date
Application number
PCT/IB2021/054246
Other languages
English (en)
Other versions
WO2021234554A3 (fr
Inventor
Chandanmal pukhraj BOTHRA
Hemanth Kumar BOTHRA
Elayaraja NATARAJAN
Chitra AJITHAN VARMA
Original Assignee
Lyrus Life Sciences Pvt Ltd
Nokha Trading Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyrus Life Sciences Pvt Ltd, Nokha Trading Llp filed Critical Lyrus Life Sciences Pvt Ltd
Priority to AU2021276914A priority Critical patent/AU2021276914A1/en
Priority to CA3176914A priority patent/CA3176914A1/fr
Publication of WO2021234554A2 publication Critical patent/WO2021234554A2/fr
Publication of WO2021234554A3 publication Critical patent/WO2021234554A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne la combinaison d'un agent actif primaire et d'un agent mucolytique en tant qu'adjuvant pour le traitement d'infections virales. La présente invention concerne la combinaison d'un agent actif primaire et d'un agent mucolytique en tant qu'adjuvant spécifiquement pour le traitement de la COVID-19. La présente invention concerne le co-conditionnement d'un agent actif primaire et d'un agent mucolytique en tant qu'adjuvant spécifiquement pour le traitement de la COVID-19. La présente invention concerne spécifiquement une composition comprenant une combinaison d'un agent antiviral en tant qu'agent actif primaire et d'un agent mucolytique en tant qu'adjuvant pour le traitement de la COVID-19. La présente invention concerne spécifiquement une composition comprenant une combinaison d'un agent anti-goutte en tant qu'agent actif primaire et d'un agent mucolytique en tant qu'adjuvant pour le traitement de la COVID-19. La présente invention concerne plus spécifiquement la composition comprenant du favipiravir en tant qu'agent actif primaire et de la carbocistéine en tant qu'adjuvant, de la colchicine en tant qu'agent actif primaire et de la carbocistéine en tant qu'adjuvant pour le traitement de la COVID-19.
PCT/IB2021/054246 2020-05-20 2021-05-18 Nouvelle composition pour le traitement d'infections virales WO2021234554A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021276914A AU2021276914A1 (en) 2020-05-20 2021-05-18 Novel composition for the treatment of viral infections
CA3176914A CA3176914A1 (fr) 2020-05-20 2021-05-18 Nouvelle composition pour le traitement d'infections virales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ININ202041021211 2020-05-20
IN202041021211 2020-05-20

Publications (2)

Publication Number Publication Date
WO2021234554A2 true WO2021234554A2 (fr) 2021-11-25
WO2021234554A3 WO2021234554A3 (fr) 2022-01-06

Family

ID=78709102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/054246 WO2021234554A2 (fr) 2020-05-20 2021-05-18 Nouvelle composition pour le traitement d'infections virales

Country Status (3)

Country Link
AU (1) AU2021276914A1 (fr)
CA (1) CA3176914A1 (fr)
WO (1) WO2021234554A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126169A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Utilisation d'un composé de carboxyméthylcystéine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309420A (zh) * 2015-07-06 2017-01-11 广州白云山医药集团股份有限公司白云山制药总厂 S-(羧甲基)-l-半胱氨酸的新用途
SG10202001878WA (en) * 2015-09-16 2020-04-29 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126169A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Utilisation d'un composé de carboxyméthylcystéine

Also Published As

Publication number Publication date
AU2021276914A1 (en) 2022-12-01
WO2021234554A3 (fr) 2022-01-06
CA3176914A1 (fr) 2021-11-25

Similar Documents

Publication Publication Date Title
TWI796665B (zh) 1'-氰基經取代碳核苷類似物之吸入式調配物
Seneviratne et al. Favipiravir in COVID-19
EP3356355B1 (fr) Composés et combinaisons pour le traitement du vih
CZ2003754A3 (cs) Léčivo pro oddálení recidivy symptomů vyvolaných herpes virem
KR20050074577A (ko) 알레르기성 비염을 치료하기 위한 항­알레르기제 및스테로이드의 용도
CN105555771A (zh) 无定形莱特莫韦及其用于口服施用的固体药物制剂
CA2671470A1 (fr) Preparation en poudre du valganciclovir
CN106860414B (zh) 一种用于抗hiv的复方制剂及其制备方法与应用
JP2003510275A (ja) ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
US10918601B2 (en) Spray-dried pharmaceutical compositions comprising active agent nanoparticles
WO2008070547A1 (fr) Formulations améliorées à base d'aciclovir
WO2014142607A1 (fr) Médicament combiné pharmaceutique
WO2021234554A2 (fr) Nouvelle composition pour le traitement d'infections virales
TW201521739A (zh) 含有局部麻醉劑之局部用抗病毒組合物及其製備方法
WO2009026790A1 (fr) Formulation de la forme cristalline d'entécavir et son procédé de préparation
WO2022199049A1 (fr) Utilisation de l'ulinastatine dans la préparation d'un médicament pour le traitement de la nouvelle pneumonie à coronavirus
US8450330B2 (en) Pharmaceutical acceptable composition containing non-steroidal anti-inflammatory drug and local anesthetics
US20240115588A1 (en) Use of proteasome inhibitors in the treatment of coronavirus infections
CN114191404A (zh) 一种多替拉韦片剂及其制备方法
CN113712931A (zh) 一种富马酸丙酚替诺福韦片剂及其制备方法
CN106474122B (zh) 一种阿莫西林克拉维酸钾的药物组合物及其应用
US20230110899A1 (en) Novel compositions for treatment of coronavirus disease
US11304947B2 (en) Compositions and methods for treating lung injuries associated with SARS-COV-2 infections
CN110013474A (zh) 非诺贝特的新用途以及针对新用途的药物
WO2023091107A1 (fr) Préparation de nouvelles formulations médicamenteuses capables de présenter un effet antiviral et investigation de leur effet contre la covid-19

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3176914

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021276914

Country of ref document: AU

Date of ref document: 20210518

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE